Documents

Q1 FY 2026 revenue up 21% YoY, forecast raised on strong oncology sales and yen weakness.

Strong oncology-driven growth and ambitious targets set for FY 2030, despite near-term headwinds.

FY 2025 profit forecast cut by JPY 106B as ADC supply strategy shifts to risk-adjusted planning.

Strong oncology sales drove double-digit revenue growth and higher profit, with robust outlook maintained.

Oncology-driven growth, ADC innovation, and global expansion set the stage for sustained leadership.

Oncology-driven revenue growth offset by higher costs and inventory write-downs in Q2 FY2025.

Strong oncology sales drove revenue and profit growth, with robust R&D and raised guidance.

Strong oncology pipeline growth, new ADC approvals, and global supply expansion drive future outlook.

Sustainability, innovation, and patient-centricity drive long-term value and global growth.

ENHERTU and Dato-DXd deliver practice-changing results in breast and ovarian cancers, supporting new standards of care.

I-DXd shows strong efficacy and safety in relapsed ES-SCLC, advancing with breakthrough status.

Robust efficacy and biomarker-driven strategies drive pipeline progress in oncology.

FY2024 saw record revenue and profit, with FY2025 targeting further growth and higher shareholder returns.